drugset / Trial / NCT02042183

Lubiprostone in Children With Functional Constipation

NCT02042183

Phase 3 Completed 606 enrolled Sucampo Pharma Americas, LLC Sucampo AG · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to determine if children (6-17 years old) with functional constipation will respond to being treated with lubiprostone for 12 weeks.

Timeline

Start
2013-12-13
Primary completion
2016-07-27
Completion
2016-07-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Lubiprostone Small molecule 12 ug Oral
Subject Lubiprostone Small molecule 24 ug Oral

Indications